{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:04:18Z","timestamp":1784541858366,"version":"3.55.0"},"reference-count":45,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15711","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:59:13Z","timestamp":1781693953000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["CD47 monoclonal antibody enhances the inhibitory effect of anti\u2011HER2 chimeric antigen receptor macrophages on ovarian cancer"],"prefix":"10.3892","volume":"32","author":[{"given":"Jie","family":"Qiao","sequence":"first","affiliation":[{"name":"School of Pharmacy, Wannan Medical College, Wuhu, Anhui 241002, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Kou","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University, Nanjing, Jiangsu 211166, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Qiu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Wannan Medical College, Wuhu, Anhui 241002, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"key20260720122116_b1-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: A review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"key20260720122116_b2-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-Expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260720122116_b3-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"116349","DOI":"10.1016\/j.bcp.2024.116349","article-title":"CAR-T therapy for ovarian cancer: Recent advances and future directions","volume":"226","author":"Xin","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"key20260720122116_b4-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-026-01792-9","article-title":"Optimizing next-generation CAR-macrophages against solid tumors: Challenges and potential strategies","volume":"10","author":"Chen","year":"2026","journal-title":"J Hematol Oncol"},{"key":"key20260720122116_b5-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","article-title":"CAR-macrophage: A new immunotherapy candidate against solid tumors","volume":"139","author":"Chen","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"key20260720122116_b6-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jare.2025.01.004","article-title":"Exploring CAR-macrophages in non-tumor diseases: Therapeutic potential beyond cancer","volume":"77","author":"Chen","year":"2025","journal-title":"J Adv Res"},{"key":"key20260720122116_b7-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: A phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"key20260720122116_b8-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1007\/s00277-025-06538-0","article-title":"Expanding the frontier of CAR therapy: Comparative insights into CAR-T, CAR-NK, CAR-M, and CAR-DC approaches","volume":"104","author":"Zhang","year":"2025","journal-title":"Ann Hematol"},{"key":"key20260720122116_b9-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","article-title":"A new era of cancer immunotherapy: Combining revolutionary technologies for enhanced CAR-M therapy","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"key":"key20260720122116_b10-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"key20260720122116_b11-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J Hematol Oncol"},{"key":"key20260720122116_b12-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"key":"key20260720122116_b13-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"e2103258","DOI":"10.1002\/adma.202103258","article-title":"Nanocomplex-mediated in vivo programming to chimeric antigen Receptor-M1 macrophages for cancer therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Adv Mater"},{"key":"key20260720122116_b14-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","article-title":"Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"key20260720122116_b15-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01734-4","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat Immunol"},{"key":"key20260720122116_b16-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"key":"key20260720122116_b17-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"key20260720122116_b18-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","article-title":"Timing of anti-PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"8","author":"Hirayama","year":"2024","journal-title":"Blood Adv"},{"key":"key20260720122116_b19-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: A phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat Cancer"},{"key":"key20260720122116_b20-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"key20260720122116_b21-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-4939-7172-5_5","article-title":"Principles and methods of immunohistochemistry","volume":"1641","author":"Ramos-Vara","year":"2017","journal-title":"Methods Mol Biol"},{"key":"key20260720122116_b22-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12967-023-04061-2","article-title":"M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors","volume":"21","author":"Huo","year":"2023","journal-title":"J Transl Med"},{"key":"key20260720122116_b23-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3390\/cancers13071664","article-title":"Novel HER2-directed treatments in advanced gastric carcinoma: AnotHER paradigm shift?","volume":"13","author":"Ricci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260720122116_b24-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"11961","DOI":"10.3390\/ijms262411961","article-title":"Molecular alterations and pathways in intrahepatic cholangiocarcinoma: Available evidence and new perspectives","volume":"26","author":"Astore","year":"2025","journal-title":"Int J Mol Sci"},{"key":"key20260720122116_b25-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"103119","DOI":"10.1016\/j.critrevonc.2020.103119","article-title":"Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma","volume":"156","author":"Lamberti","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20260720122116_b26-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/13543784.2021.1854724","article-title":"Experimental HER2-targeted therapies for biliary tract cancer","volume":"30","author":"Rizzo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"key20260720122116_b27-ol-32-2-15711","article-title":"Elacestrant in metastatic breast cancer: Current advancements and future perspectives","author":"Sahin","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20260720122116_b28-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"102924","DOI":"10.1016\/j.ctrv.2025.102924","article-title":"Post-progression treatment options after CDK4\/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"135","author":"Sahin","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"key20260720122116_b29-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(23)02296-1","article-title":"Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer","volume":"402","author":"Smyth","year":"2023","journal-title":"Lancet"},{"key":"key20260720122116_b30-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"key20260720122116_b31-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: Potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"key20260720122116_b32-ol-32-2-15711","first-page":"eabj5501","article-title":"SLAMF3 and SLAMF4 are immune checkpoints that constrain macrophage phagocytosis of hematopoietic tumors","volume":"7","author":"Li","year":"2022","journal-title":"Sci Immunol"},{"key":"key20260720122116_b33-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"929339","DOI":"10.3389\/fimmu.2022.929339","article-title":"Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages","volume":"13","author":"Zeller","year":"2022","journal-title":"Front Immunol"},{"key":"key20260720122116_b34-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1038\/s41467-025-60456-3","article-title":"CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRP\u03b1-CD47 to suppress tumor growth","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"key20260720122116_b35-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"key20260720122116_b36-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12943-024-02184-8","article-title":"Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol Cancer"},{"key":"key20260720122116_b37-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","article-title":"The application of HER2 and CD47 CAR-macrophage in ovarian cancer","volume":"21","author":"Chen","year":"2023","journal-title":"J Transl Med"},{"key":"key20260720122116_b38-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","article-title":"The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors","volume":"11","author":"Hadiloo","year":"2023","journal-title":"Biomark Res"},{"key":"key20260720122116_b39-ol-32-2-15711","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2026.02.008","article-title":"Driving CAR therapies beyond T cells","author":"Madsen","year":"2026","journal-title":"Trends Cancer"},{"key":"key20260720122116_b40-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ijms27031292","article-title":"Targeting macrophages in immunotherapy: The ascent of CAR-Macrophages","volume":"27","author":"Nadella","year":"2026","journal-title":"Int J Mol Sci"},{"key":"key20260720122116_b41-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"189294","DOI":"10.1016\/j.bbcan.2025.189294","article-title":"CD47 as a potent target in cancer immunotherapy: A review","volume":"1880","author":"Ahvati","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"key20260720122116_b42-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s42003-025-09331-x","article-title":"IL-21 promotes the anti-tumor effect of anti-CD47 chimeric antigen receptor macrophages in ovarian cancer","volume":"9","author":"Chen","year":"2025","journal-title":"Commun Biol"},{"key":"key20260720122116_b43-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","article-title":"Emerging phagocytosis checkpoints in cancer immunotherapy","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"key20260720122116_b44-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"key20260720122116_b45-ol-32-2-15711","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s43018-025-00950-1","article-title":"An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma","volume":"6","author":"Jing","year":"2025","journal-title":"Nat Cancer"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:21:23Z","timestamp":1784539283000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15711","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}